Key result
HDL cholesterol efflux capacity shows no link to major cardiovascular events in hemodialysis patients.
Why the study?
Does HDL cholesterol efflux capacity predict cardiovascular risk in patients with type 2 diabetes mellitus on hemodialysis?
Cohort (n=1,147)
Does HDL cholesterol efflux capacity predict cardiovascular risk in patients with type 2 diabetes mellitus on hemodialysis?
Hazard Ratio: 0.96 (95% CI 0.88–1.06)
p-value: p=0.42
HDL cholesterol efflux capacity is not a prognostic cardiovascular risk marker in patients with type 2 diabetes on hemodialysis.
No takes yet. Share an insight, caveat, or question.
HDL efflux capacity lacks prognostic value for cardiovascular events in hemodialysis; leaves open its role as biomarker or target in uremic disease.
Kopecky et al. (2016) conducted a cohort in Type 2 diabetes mellitus on hemodialysis (n=1,147). HDL cholesterol efflux capacity was evaluated on Composite of cardiac death, nonfatal myocardial infarction, and stroke (HR 0.96, 95% CI 0.88 to 1.06, p=0.42). HDL cholesterol efflux capacity was not associated with the composite of cardiac death, nonfatal myocardial infarction, and stroke in hemodialysis patients (HR 0.96; 95% CI 0.88-1.06; P=0.42).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: